Background: Optimal treatment of children with congenital hypothyroidism (CHT) is still debated. Our objective was to evaluate whether early undertreatment (UT) and overtreatment (OT) influence cognitive development at age 11 years. Methods: Sixty-one patients (27 severe CHT, 34 mild CHT) were psychologically tested at ages 1.8 (Mental Development Index), 6 [intelligence quotient (IQ) 6], and 11 years (IQ11). Scores for cognitive development were related to initial levels of TSH normalization (fast, moderate, or slow) and to total durations of theUTandOTepisodes within the first 2 years of life (no, short, or long UT/OT). UT and OT were defined as a free T4 (fT 4) concentration below or above the individual fT4 steadystate concentration range (±2 SD). Results: Patients with fast and moderate TSH normalization had higher Mental Development Index scores than patients with slow TSH normalization; 14.2 and 7.7 points higher, respectively (P = .001). TSH normalization had no significant effect on IQ11. Patients with long and short overtreatment had IQ11s that were -17.8 and -13.4 points lower, respectively, than the IQ11s of patients withnoovertreatment (P=.014).UTwithoutOTwasassociated with normal development scores, but UT withOTwas associated with-14.7 points lower IQ11s than UT withoutOT(P=.005). Conclusions: Our study suggests that CHT overtreatment during the first 2 years leads to lowered cognitive outcomes at 11 years, whereas undertreatment, if not complicated by overtreatment, results in a normal cognitive development. Fast TSH normalization at initial treatment leads to above-normal development scores at a young age but does not affect IQ at age 11 years. Copyright

dx.doi.org/10.1210/jc.2013-2175, hdl.handle.net/1765/69355
Journal of Clinical Endocrinology and Metabolism
Department of Clinical Chemistry

Bongers-Schokking, J.J, Resing, W.C.M, de Rijke, Y.B, de Ridder, M.A.J, & de Muinck Keizer-Schrama, S.M.P.F. (2013). Cognitive development in congenital hypothyroidism: Is overtreatment a greater threat than undertreatment?. Journal of Clinical Endocrinology and Metabolism, 98(11), 4499–4506. doi:10.1210/jc.2013-2175